Ana Herrero Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana Herrero Ruiz has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ana Isabel Sánchez Marcos
Complejo Asistencial Universitario de Salamanca
1 shared publication C. Higueruela-Mínguez
Service of Endocrinology and Nutrition, University Clinical Hospital of Salamanca, Paseo de San Vicente No. 58, 37007 Salamanca, Spain
1 shared publicationH. S. Villanueva-Alvarado
Service of Endocrinology and Nutrition, University Clinical Hospital of Salamanca, Paseo de San Vicente No. 58, 37007 Salamanca, Spain
1 shared publicationJ. J. Corrales
Department of Medicine and Service of Endocrinology and Nutrition, University of Salamanca, University Clinical Hospital of Salamanca, Salamanca, Spain
1 shared publication- J. J. Corrales-Hernández
Service of Endocrinology and Nutrition, University Clinical Hospital of Salamanca, Paseo de San Vicente No. 58, 37007 Salamanca, Spain
1 shared publication J. M. Miralles
Department of Medicine and Service of Endocrinology and Nutrition, University of Salamanca, University Clinical Hospital of Salamanca, Salamanca, Spain
1 shared publication
Latest Publications
- Open Access
- 14 December 2021
- Published by Ediciones Universidad de Salamanca in Revista ORL
- Vol. 13 (2) , e27141
Diagnóstico del carcinoma medular de tiroides
Introducción: El carcinoma medular de tiroides (CMT) es un tumor maligno neuroendocrino poco frecuente derivado de las células parafoliculares o células C del tiroides. En el momento del diagnóstico presentan metástasis ganglionares más del 50% y a distancia el 10%. Su pronóstico depende en gran parte del estadio del tumor, por lo que su diagnóstico temprano es fundamental. Objetivo: El objetivo de este trabajo es realizar una revisión actualizada sobre el abordaje diagnóstico del CMT. Síntesis: La ecografía es la principal herramienta en la estratificación del nódulo tiroideo, pero la mayor parte de los estudios se han centrado en el carcinoma papilar de tiroides. En el caso del CMT las características ecográficas sospechosas de malignidad suelen ser menos frecuentes y esto podría conducir a un retraso diagnóstico y terapéutico, por lo que se debe combinar con técnicas diagnósticas adicionales. En estos tumores la sensibilidad del estudio citológico del nódulo mediante punción aspiración con aguja fina generalmente es baja, y en aquellos casos de sospecha de CMT se recomienda realizar inmunohistoquímica para calcitonina y determinar la calcitonina en el aspirado de la punción. La calcitonina plasmática es el marcador más sensible para el diagnóstico de estos pacientes, pero su determinación rutinaria en el estudio del nódulo tiroideo es controvertida. Sus niveles se relacionan con la masa de células C y la presencia de metástasis ganglionares. Si son superiores a 500 pg/ml se recomienda realizar estudio de extensión con pruebas de imagen complementarias por sospecha de enfermedad metastásica. Es importante solicitar estudio genético a todos los pacientes, ya que el 25% son hereditarios formando parte de la neoplasia endocrina múltiple tipo 2 asociada a mutación en el gen RET.
- 14 December 2021
- Published by Ediciones Universidad de Salamanca in Revista ORL
- Vol. 13 (2) , e27141
Open AccessDiagnóstico del carcinoma medular de tiroides
Introducción: El carcinoma medular de tiroides (CMT) es un tumor maligno neuroendocrino poco frecuente derivado de las células parafoliculares o células C del tiroides. En el momento del diagnóstico presentan metástasis ganglionares más del 50% y a distancia el 10%. Su pronóstico depende en gran parte del estadio del tumor, por lo que su diagnóstico temprano es fundamental. Objetivo: El objetivo de este trabajo es realizar una revisión actualizada sobre el abordaje diagnóstico del CMT. Síntesis: La ecografía es la principal herramienta en la estratificación del nódulo tiroideo, pero la mayor parte de los estudios se han centrado en el carcinoma papilar de tiroides. En el caso del CMT las características ecográficas sospechosas de malignidad suelen ser menos frecuentes y esto podría conducir a un retraso diagnóstico y terapéutico, por lo que se debe combinar con técnicas diagnósticas adicionales. En estos tumores la sensibilidad del estudio citológico del nódulo mediante punción aspiración con aguja fina generalmente es baja, y en aquellos casos de sospecha de CMT se recomienda realizar inmunohistoquímica para calcitonina y determinar la calcitonina en el aspirado de la punción. La calcitonina plasmática es el marcador más sensible para el diagnóstico de estos pacientes, pero su determinación rutinaria en el estudio del nódulo tiroideo es controvertida. Sus niveles se relacionan con la masa de células C y la presencia de metástasis ganglionares. Si son superiores a 500 pg/ml se recomienda realizar estudio de extensión con pruebas de imagen complementarias por sospecha de enfermedad metastásica. Es importante solicitar estudio genético a todos los pacientes, ya que el 25% son hereditarios formando parte de la neoplasia endocrina múltiple tipo 2 asociada a mutación en el gen RET.
- Open Access
Clinical and biochemical correlates of male hypogonadism in type 2 diabetes
Summary: The origin of hypogonadism, a condition including both symptoms and biochemical criteria of androgen deficiency, in type 2 diabetes is poorly known. In a cross‐sectional study of 267 unselected patients, we analyzed the potential correlation of several clinical and biochemical variables as well as chronic micro‐ and macrovascular diabetic complications with hypogonadism. Hypogonadism was present in 46 patients (17.2%) using a cutoff of total testosterone 10.4 nmol/L and in 31 (11.6%) with a cutoff of 8 nmol/L. Among these patients, hypogonadotropic hypogonadism was the most prevalent form (82.6%). Compared to eugonadal subjects, hypogonadal men had significantly lower glomerular filtration rate (67.1 ± 23.4 vs. 78.4 ± 24.6 mL/min/1.73 m2, p = 0.005) and higher prevalence of chronic kidney disease (43.5% vs. 20.4%, p = 0.002), abnormal liver function tests (26.7% vs. 12%, p = 0.019), and psychiatric treatment (23.9% vs. 10.4%, p = 0.025). Total testosterone levels correlated inversely with age (R = −0.164, p = 0.007), fasting blood glucose (R = −0.127, p = 0.037), and triglycerides (R = −0.134, p = 0.029) and directly with glomerular filtration rate (R = 0.148, p = 0.015). Calculated free testosterone and bioavailable testosterone correlated directly with hemoglobin (R = 0.171, p = 0.015 and R = 0.234, p = 0.001, respectively). Multivariate logistic regression analysis, after adjusting for relevant confounding variables, showed that age >60 years (OR = 3.58, CI 95% = 1.48–8.69, p = 0.005), body mass index >27 kg/m2 (OR = 2.85, CI 95% = 1.14–7.11, p = 0.025), hypertriglyceridemia (OR = 2.16, CI 95% = 1.05–4.41, p = 0.035), glomerular filtration rate 2 (OR = 2.51, CI 95% = 1.19–5.29, p = 0.015), and abnormal liver function tests (OR = 3.57, CI 95% = 1.48–8.60, p = 0.005) were independently associated with male hypogonadism. Although older age, body mass index, and hypertriglyceridemia have been previously related to hypogonadism, our results describe that chronic kidney disease and abnormal liver function tests are independently correlated with hypogonadism in type 2 diabetic men.
Open AccessClinical and biochemical correlates of male hypogonadism in type 2 diabetes
Summary: The origin of hypogonadism, a condition including both symptoms and biochemical criteria of androgen deficiency, in type 2 diabetes is poorly known. In a cross‐sectional study of 267 unselected patients, we analyzed the potential correlation of several clinical and biochemical variables as well as chronic micro‐ and macrovascular diabetic complications with hypogonadism. Hypogonadism was present in 46 patients (17.2%) using a cutoff of total testosterone 10.4 nmol/L and in 31 (11.6%) with a cutoff of 8 nmol/L. Among these patients, hypogonadotropic hypogonadism was the most prevalent form (82.6%). Compared to eugonadal subjects, hypogonadal men had significantly lower glomerular filtration rate (67.1 ± 23.4 vs. 78.4 ± 24.6 mL/min/1.73 m2, p = 0.005) and higher prevalence of chronic kidney disease (43.5% vs. 20.4%, p = 0.002), abnormal liver function tests (26.7% vs. 12%, p = 0.019), and psychiatric treatment (23.9% vs. 10.4%, p = 0.025). Total testosterone levels correlated inversely with age (R = −0.164, p = 0.007), fasting blood glucose (R = −0.127, p = 0.037), and triglycerides (R = −0.134, p = 0.029) and directly with glomerular filtration rate (R = 0.148, p = 0.015). Calculated free testosterone and bioavailable testosterone correlated directly with hemoglobin (R = 0.171, p = 0.015 and R = 0.234, p = 0.001, respectively). Multivariate logistic regression analysis, after adjusting for relevant confounding variables, showed that age >60 years (OR = 3.58, CI 95% = 1.48–8.69, p = 0.005), body mass index >27 kg/m2 (OR = 2.85, CI 95% = 1.14–7.11, p = 0.025), hypertriglyceridemia (OR = 2.16, CI 95% = 1.05–4.41, p = 0.035), glomerular filtration rate 2 (OR = 2.51, CI 95% = 1.19–5.29, p = 0.015), and abnormal liver function tests (OR = 3.57, CI 95% = 1.48–8.60, p = 0.005) were independently associated with male hypogonadism. Although older age, body mass index, and hypertriglyceridemia have been previously related to hypogonadism, our results describe that chronic kidney disease and abnormal liver function tests are independently correlated with hypogonadism in type 2 diabetic men.
- Open Access
- 1 November 2017
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2017, 1-5
Coexistence of GH-Producing Pituitary Macroadenoma and Meningioma in a Patient with Multiple Endocrine Neoplasia Type 1 with Hyperglycemia and Ketosis as First Clinical Sign
We present the clinical case of a patient who was admitted with an onset of diabetes mellitus (DM) with associated ketosis and whose clinical, hormonal, and radiological evolution revealed the presence of primary hyperparathyroidism, pancreatic neuroendocrine tumor, and GH-producing pituitary macroadenoma in the context of multiple endocrine neoplasia type 1 (MEN1). DM is relatively common in cases of acromegaly, but it is not generally associated with ketosis. Simultaneously, the patient presented a meningioma, which is associated with pituitary macroadenoma only in extremely rare cases.
- 1 November 2017
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2017, 1-5
Open AccessCoexistence of GH-Producing Pituitary Macroadenoma and Meningioma in a Patient with Multiple Endocrine Neoplasia Type 1 with Hyperglycemia and Ketosis as First Clinical Sign
We present the clinical case of a patient who was admitted with an onset of diabetes mellitus (DM) with associated ketosis and whose clinical, hormonal, and radiological evolution revealed the presence of primary hyperparathyroidism, pancreatic neuroendocrine tumor, and GH-producing pituitary macroadenoma in the context of multiple endocrine neoplasia type 1 (MEN1). DM is relatively common in cases of acromegaly, but it is not generally associated with ketosis. Simultaneously, the patient presented a meningioma, which is associated with pituitary macroadenoma only in extremely rare cases.